Accelerating the creation of a smoke-free future
Diseases and deaths associated with smoking are amongst the most preventable. Despite the widespread knowledge that smoking is harmful, hundreds of millions of people continue to smoke. Even though there are 1.2 billion smokers in the world and smoking kills about 8 million people a year, people continue to smoke for the nicotine that they are addicted to. However, it’s not the nicotine that causes harm, it’s the harmful chemicals that accompany the nicotine found in smoke when tobacco is burnt.
Helping to shape the future.
Our team of leading scientific and regulatory experts across the global nicotine market are here to help you navigate through the product life cycle journey for your chosen regulatory pathway, these include:
Our experienced team have worked on major tobacco harm reduction regulatory projects to enable smokers to access scientifically substantiated reduced-risk products and are ready to advise you on tailor-made scientific strategies in areas including product development, regulatory submissions and post marketing surveillance activities.
Helping innovative companies get their Next Generation Nicotine Delivery Products (NGPs) to market
Helping to shape the future strategy of regulated Next Generation Nicotine Delivery Product (NGP) markets
Understanding clients needs and scoping the journey ahead
Maintaining and keeping your product on the market
Our integrated laboratory services provide scientific support and data generation for your NGP project.
Understanding the chemistry of your Next Generation Nicotine Delivery Products (NGPs)
Understand the potential human health impact of your Next Generation Nicotine Delivery Products (NGPs)
Understand the potential human health impact of your Next Generation Nicotine Delivery Products (NGPs)
Broughton's Head of Regulatory Affairs, Lloyd Smart discusses the latest UK Medicines & Healthcare products Regulatory Agency (MHRA) guidance on licensing electronic cigarettes as medicines and important points for applicants to consider.
Broughton's Head of Regulatory Affairs, Lloyd Smart discusses Food and Drug Administration (FDA) final ruling for Premarket Tobacco Product Applications (PMTA) and what this means for Electronic Nicotine Delivery System (ENDS) companies.
Broughton's Head of Regulatory Affairs, Lloyd Smart discusses the Australian Government's recent announcement regarding existing nicotine vaping laws which now rule out importation of certain products.
Broughton's Chief Regulatory Officer, Dr Nveed Chaudhary shares his post-event reflections on Global Tobacco Nicotine Forum (GTNF) 2021.
Broughton Head of Scientific Affairs, Paul Hardman has recently published an article with leading sector publication Tobacco Reporter.
Discover our videos, brochures, infographics and much more.
Understand what’s involved in a PMTA and how the recommendations relate to your ENDS business.
Learn more about the process for toxicology risk assessments for ENDS products.
Get the straightforward answers you’re looking for when it comes to TPD and TRPR analysis.
